TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer
International Journal of Drug Delivery Technology · 13.08.2026 · 16 (75s)
DOI: 10.25258/ijddt.16.75s.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 13.08.2026. Verfasst von Orcun Can und 1 weiteren Autor:innen.
Abstract (Originalsprache)
.
Zitieren
APA
Can, O., & Uras, C. (2026). TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer. International Journal of Drug Delivery Technology, 16(75s). https://doi.org/10.25258/ijddt.16.75s.6
Vancouver
Can O, Uras C. TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer. International Journal of Drug Delivery Technology. 2026;16(75s). doi:10.25258/ijddt.16.75s.6
BibTeX
@article{Can2026,
author = {Can, Orcun and Uras, Cihan},
title = {TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {75s},
doi = {10.25258/ijddt.16.75s.6}
}
EUVIMED